Fundamental Analysis Stories

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:0.9em;;'>AZZ</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
AZZ Receivables Turnover is fairly stable at the moment as compared to the past year. AZZ reported Receivables Turnover of 4.93 in 2019. Accounts Payable Turnover is likely to rise to 21.08 in 2020, whereas Revenue Per Employee is likely to drop slightly above 225.4 K in 2020. AZZ Inc is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 13th of October 2020. The stock is in a buyout trend. Many investors are getting excited about industrials space, let's analyze if AZZ Inc fundamentals are strong enough to attract traders. We will look into reasons why it is still very possible for the company to generate above-average returns. The entity slowly supersedes the market. We can now inspect AZZ as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>FP</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Five Prime Accounts Payable Turnover is fairly stable at the moment as compared to the past year. Five Prime reported Accounts Payable Turnover of 7.01 in 2019. Accrued Expenses Turnover is likely to rise to 0.80 in 2020, whereas Net Income Per Employee is likely to drop (1.6 M) in 2020. The upcoming quarterly report is expected on the 4th of November 2020. The stock experiences an active upward rally. Healthcare space may be getting hot again, let's check if Five Prime Therapeutics is sending any bullish signals to investors. We will analyze why Five Prime investors may still consider a stake in the business. Five Prime Therapeutics current chance of bankruptcy is under 41 percent. Will investors continue to be optimistic, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>DI</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Even with relatively sluggish basic indicators, Dillards may actually be approaching a critical reversion point that can send shares even higher in November 2020. We currently estimate Dillards as overvalued. The real value is approaching 34.48 per share.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>IG</div>
  over a month ago at Macroaxis 
By Vlad Skutelnik
Ion Geophysical Invested Capital Average is quite stable at the moment as compared to the past year. The company's current value of Invested Capital Average is estimated at 223.31 Million. Market Capitalization is expected to rise to about 126.5 M this year, although the value of Net Income Per Employee will most likely fall to (100.2 K). If you have been following Ion Geophysical you may be considering picking up. Let's check if persistent technical and fundamental indicators will continue to push the price to rise for Ion Geophysical's institutional investors. Will institutional investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;;'>RI</div>
  over a month ago at Macroaxis 
By Vlad Skutelnik
RPM International Free Cash Flow is relatively stable at the moment as compared to the past year. The company's current value of Free Cash Flow is estimated at 347.17 Million. Market Capitalization is expected to hike to about 6.5 B this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to nearly 509.8 M. RPM International is scheduled to announce its earnings today. The next earnings report is expected on the 13th of January 2021. Is basic materials space attracting new stakeholders, let's check if RPM International is sending any bullish signals. We will evaluate if RPM International shares are reasonably priced going into November. RPM International barely shadows the market. We can now summarize RPM International as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;;'>ET</div>
  over a month ago at Macroaxis 
By Achuva Shats
Eidos Therapeutics Net Cash Flow or Change in Cash and Cash Equivalents is fairly stable at the moment as compared to the past year. Eidos Therapeutics reported Net Cash Flow or Change in Cash and Cash Equivalents of 34.01 Million in 2019. Issuance Purchase of Equity Shares is likely to rise to about 48.9 M in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (38.4 M) in 2020. There are many examples of prices sliding after a drastic change in one of the basic indicators. In this short article, we will break down a few of Eidos Therapeutics' essential fundamentals. We will analyze why Eidos Therapeutics investors may still consider a stake in the business. The company current probability of distress is under 1 percent. Will investors continue to be optimistic, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#9CBEFD;color: #ffffff;font-size:1.1em;;'>ET</div>
  over a month ago at Macroaxis 
By Achuva Shats
Enlivex Therapeutics Tangible Assets Book Value per Share are fairly stable at the moment as compared to the past year. Enlivex Therapeutics reported Tangible Assets Book Value per Share of 2.03 in 2019. Depreciation Amortization and Accretion is likely to climb to about 403.5 K in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (8.6 M) in 2020. One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will focus on Enlivex Therapeutics. We will cover the possibilities of making Enlivex Therapeutics into a steady grower in November. Will sophisticated investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;;'>AH</div>
  over a month ago at Macroaxis 
By Gabriel Shpitalnik
The next fiscal quarter end is expected on the 30th of September 2020. The stock is undergoing an active upward rally. Although many conservative investors are getting more into healthcare space, we should study Axcella Health's current fundamentals in more details. What exactly are Axcella Health shareholders getting in October? The company current odds of financial distress is over 66%. Are Axcella Health investors still optimistic?
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>AG</div>
  over a month ago at Macroaxis 
By Ellen Johnson
In spite of fairly conflicting technical and fundamental indicators, ARC GROUP may actually be approaching a critical reversion point that can send shares even higher in October 2020. The entity almost neglects market trends. We can now recap ARC GROUP as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;;'>SS</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Even with relatively weak basic indicators, Sky Solar may actually be approaching a critical reversion point that can send shares even higher in October 2020. Sky Solar Holdings probability of distress is under 39 percent. Will Sky Solar retail investors continue to take over in October?